Oxolife focuses on female fertility within the healthcare sector
Oxolife focuses on female fertility within the healthcare sector. The company is developing OXO-001, a non-hormonal oral drug that seeks to improve embryo implantation and increase live birth rates for women undergoing assisted reproductive technologies. Oxolife's research also extends to restoring fertility in women with polycystic ovary syndrome (PCOS), a common cause of infertility.